Ibrahim Yakoub-Agha

Ibrahim Yakoub-Agha

Ibrahim Yakoub-Agha

MD.PhD, HDR, PU-PH , Hematology and Cell Therapy Clinical advisor

Professor Ibrahim Yakoub-Agha has a professional background in the field of hematology, specializing in medical biology and clinical hematology. He successfully completed his four-year residency in Medical Biology at Brest University Hospital from 1986 to 1990, followed by a two-year Clinical Hematology fellowship at the University of Paris VI from 1990 to 1992. Furthermore, Professor Yakoub-Agha earned a University Diploma of Oncology at the University of Paris XI/Institut Gustave Roussy in 1995. His dedication to academic and clinical excellence is evident in his completion of two years of fellowship in Allogeneic Hematopoietic Cell Transplantation at Saint-Louis University Hospital in Paris from 1996 to 1998. Professor Yakoub-Agha achieved his PhD degree at Lille University Hospital and has since been appointed as a Professor of Hematology. He currently serves as the head of the Hematopoietic Stem Cell Transplantation Unit, a position he has held since 2008. In addition to his academic roles, Professor Yakoub-Agha is actively involved in professional organizations and has assumed leadership positions. He currently holds the position of Chair of the EBMT (European Society for Blood and Marrow Transplantation) Practice Harmonization and Guidelines. His leadership extends to his past roles as Chair of the Chronic Malignancies Working Party (CMWP) of EBMT from 2018 to 2022 and as the Past President of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) from 2012 to 2016. Professor Yakoub-Agha has contributed to the scientific community through his role as the Editor in Chief of "Current Research in Translational Medicine.". His research output includes authoring or co-authoring more than 500 scientific articles, with a primary focus on allogeneic hematopoietic cell transplantation and cellular therapy. His research encompasses studies related to patients with Myelofibrosis, myelodysplastic syndrome, multiple myeloma, as well as immune effector cells such as CAR T cells. Additionally, he has contributed to various referential textbooks by writing several chapters.

Get in Touch With Us

You can contact us for any inquiries and needs regarding Cell Therapy, Allogeneic Treatment, Immunotherapy, and Genetic Therapy.